Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 4/20 | 0.60 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.60 |
| ▸ | ITGB2 | P05107 | 11/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 11/20 | 0.53 |
| ▸ | ITGAL | P20701 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829144 | 0.85 | PDE7A (0.53) | PDE7APDE7BITGB2ICAM1ITGAL | |
| SCHEMBL3542423 | 0.82 | PDE7A (0.57) | PDE7APDE7BITGB2ICAM1ITGAL | |
| SCHEMBL3545049 | 0.82 | PDE7A (0.57) | PDE7APDE7BITGB2ICAM1ITGAL | |
| SCHEMBL11824181 | 0.82 | PDE7A (0.56) | PDE7APDE7BRHEBLMNA | |
| SCHEMBL3165346 | 0.82 | ITGB2 (0.72) | PDE7AITGB2ICAM1ITGALMEN1 | |
| SCHEMBL3550135 | 0.79 | ATM (0.54) | PDE7APDE7BITGB2ICAM1ITGAL | |
| SCHEMBL3541611 | 0.78 | HTR1A (0.54) | PDE7APDE7BMEN1ALDH1A1MAPT | |
| SCHEMBL1341957 | 0.78 | ITGB2 (0.62) | PDE7AITGB2ICAM1ITGALMEN1 | |
| Hydrochloric Acid SCHEMBL7604738 | 0.77 | ITGB2 (0.77) | PDE7APDE7BITGB2ICAM1ITGAL | |
| SCHEMBL29543575 | 0.77 | LMNA (0.57) | PDE7APDE7BMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
| EP-1626720-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | PDE7A 711/4885PDE7B 500/4885ITGB2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.